SILO PHARMA, INC. (SILO)

Every figure this model derived for SILO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 5,227,242 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 5,713,526 AssetsCurrent 2026-06-30
current liabilities 1,065,733 LiabilitiesCurrent 2026-06-30
equity 4,886,290 StockholdersEquity 2026-06-30
interest expense 39,826 InterestExpenseNonoperating 2026-06-30
ocf -3,340,255 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 54,077 Revenues 2026-06-30
sbc 195,369 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SILO on one particular measure came for.

RatioValue
current ratio5.53
current ratio reported5.36
deferred revenue growth-53.9
dilution pct127.88
growth cv1.97
interest cover-112.03
revenue growth-25.0
revenue growth per share-67.09
rule of 40-8275.46
sbc pct revenue361.28

What to be careful about

What this model itself distrusts about SILO's figures. Written by the derivation as it ran, not added afterwards.